Business

AstraZeneca has announced that it will "expand the savings programs for its entire US inhaled respiratory portfolio," capping costs at $35 per month for "eligible patients" as of June 1, 2024, while noting that "terms and conditions apply." Inhalers covered by the program include Airsupra albuterol / budesonide MDI, Bevespi Aerosphere glycopyrrolate / formoterol … [Read more...] about AstraZeneca follows Boehringer Ingelheim in capping inhaler costs for some US patients

Boehringer Ingelheim said that "eligible patients" will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol SMI, and Striverdi Respimat olodaterol SMI. According to the company, … [Read more...] about Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients

Nocion Therapeutics has announced that it raised $62 million in a Series B funding led by Monograph Capital and Arkin Bio Capital. Proceeds will be used to support a Phase 2b trial of its taplucainium (NTX-1175) inhaled dry powder for the treatment of chronic cough, the company said. In January 2020, Pulmatrix said that it had signed a deal to evaluate the use of … [Read more...] about Nocion raises $62 million for Phase 2b study of taplucainium DPI for the treatment of chronic cough

The Patient-Centric Design award at CPHI Pharmapack 2024 went to Florida-based Dr. Ferrer BioPharma for its GentleMist nozzle for intranasal delivery devices, which was developed as part of a partnership with researchers at South Dakota State University, Bona Pharma, and the Cleveland Clinic. According to the company, "GentleMist Technology utilizes advanced fluid … [Read more...] about Dr. Ferrer BioPharma wins Pharmapack award for its GentleMist nasal delivery technology

Cyrano Therapeutics said that the company will use proceeds from a $9 million Series B financing round to fund an ongoing Phase 2 trial of CYR-064 theophylline nasal spray for the treatment of loss of smell due to viral infection. Cyrano previously announced in December 2020 that it had raised $12.8 million in Series A financing for a Phase 2 trial of CYR-064. In … [Read more...] about Cyrano raises $9 million for continued development of CYR-064 intranasal theophylline for the treatment of hyposmia

Essential Pharma announced that it has acquired European rights to Teva's Colobreathe colistimethate sodium inhalation powder from Teva. Colobreathe, which was developed by Forest Laboratories, was approved by the EMA for the treatment of P. aeruginosa infections in cystic fibrosis patients aged 6 and older in 2012. According to Essential, Colobreathe is marketed in … [Read more...] about Essential Pharma acquires European rights to Colobreathe colistimethate sodium DPI from Teva

Atai Life Sciences announced that it has invested a total of $50 million to acquire 35.5% of Beckley Psytech, which is developing BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin). Atai's subsidiary Innaris Bio is developing a gelling excipient for use in intranasal drugs for the treatment of mental health disorders. The deal includes the right of first … [Read more...] about Atai Life Sciences announces strategic investment in Beckley Psytech